drugset / Trial / NCT03056495
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
Phase 1
Terminated
9 enrolled
German Center for Neurodegenerative Diseases (DZNE)
University Hospital, Bonn · collabUniversity of Göttingen · collab
NaSingle-groupOpen-labelBasic science
Summary
This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55 and 90 years with mild symptoms. The MTD in this study is defined as the dose that leads to maximum toxicity with Common Toxicity Criteria (CTC) grade 1 symptoms.The safety and tolerability of Vorinostat in this group of study participants should be tested.
Timeline
- Start
- 2017-09-28
- Primary completion
- 2024-03-04
- Completion
- 2024-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 100 mg | — |
| Subject | Vorinostat | Small molecule | 200 mg | — |
| Subject | Vorinostat | Small molecule | 300 mg | — |
| Subject | Vorinostat | Small molecule | 400 mg | — |